DB19231InvestigationalGene Therapies
Quaratusugene ozeplasmid is under investigation in clinical trial NCT05062980 (Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-small Lung Cancer).
- Also known as
- Dna (synthetic plasmid vector plj143/kgb2/tusc2) · Dna-lipid complex (dotap/cholesterol) plasmid vector (plj143/pkgb2/tusc2, baylor) expressing the tusc2 gene · Reqorsa
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Quaratusugene ozeplasmid, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account